Quick answer
The KLOW Stack blends GHK-Cu, KPV, BPC-157 and TB-500; sourcing it well means per-component identity, blend-ratio evidence and a lot-matched CoA.
- Purity: ≥98% by HPLC listed for the 80 mg blend
- Identity: each component needs its own mass confirmation
- Blend ratio: ask how composition was verified
- Documents: CoA page; vial on the KLOW Stack page
- Research use: For laboratory research use only; not for human consumption.
For laboratory research use only; not for human consumption.
What V8's lab reports contain. The lab reports published for V8 lots, issued by Accumark Labs, show HPLC purity, identity and measured quantity and, for most lots, endotoxin (LAL) and a rapid PCR sterility screen. See the COA library for the report on a specific lot.
What the KLOW Stack is
The KLOW Stack combines four distinct research peptides (GHK-Cu, KPV, BPC-157 and TB-500) in a single lyophilized blend. The V8 Peptides product is an 80 mg blend vial. Sourcing a pre-mixed blend is a different problem from sourcing a single compound: a supplier has to get four separate synthesis and purification processes right, then combine them at the intended mass ratio, before a lab ever opens the vial. A label that says "KLOW Stack" tells you nothing about whether all four components are present at the intended ratio and purity. Only analytical documentation does.
| Component | Type | Approximate mass |
|---|---|---|
| GHK-Cu | Copper(II) complex of the tripeptide Gly-His-Lys | GHK about 340 Da; complex about 400 Da |
| KPV | Tripeptide Lys-Pro-Val | About 342 Da |
| BPC-157 | 15-residue synthetic peptide | About 1,419 Da |
| TB-500 | Thymosin beta-4-derived peptide | Depends on the stated sequence; see the CoA |
Because the components span from a roughly 340 Da tripeptide to a multi-kilodalton peptide, they behave very differently on a column and in a mass spectrometer. That is the core reason a single "purity" number is not enough for a blend.
What to verify before ordering
- Purity for each component. GHK-Cu, KPV, BPC-157 and TB-500 should each be manufactured to research-grade purity before blending, not averaged together as a single number. The V8 Peptides product page lists ≥98% by HPLC for the blend. Background on why each component matters independently is in the KLOW Stack research overview.
- Blend formulation accuracy. The four peptides should be present at a documented, consistent mass ratio per vial. A supplier that cannot describe how it verifies formulation accuracy (gravimetric control, mass spectrometry confirmation of each component's presence) is asking a lab to trust an unverified mixing process.
- Mass-spectrometry identity per component. With four different peptides present, a single HPLC run cannot reliably resolve and confirm all of them; look for evidence that each component was identity-confirmed. See HPLC vs. mass spectrometry.
- Batch-specific certificate of analysis covering the blended lot actually shipped, not component data pulled from unrelated production runs. See how to read a CoA.
- Lyophilized form and sensible handling. The blend should arrive lyophilized, with storage and reconstitution information specific to a multi-component mixture. See KLOW Stack reconstitution and storage.
Why blend verification matters more than single-peptide sourcing
A single-compound vial fails in one of two ways: wrong compound, or wrong purity. A blended vial has more ways to fail. One component can be absent or under-represented relative to the others while the vial still looks correct on a cursory check, which is why formulation-level documentation matters as much as purity for any combination product. Endotoxin control is a particular concern for a blend that includes KPV, since contamination that provokes an inflammatory response in cell-culture work can confound exactly the kind of signaling research the stack is used for. The difference between component-level and blend-level verification is covered in KLOW Stack purity testing.
How the components complicate the analysis
GHK and KPV are very small and polar, so they elute early on a reversed-phase gradient, close to salts and other unretained material, where integration is hardest. BPC-157, being proline-rich and mid-sized, elutes mid-gradient, and the larger TB-500 component elutes later. Copper in GHK-Cu adds a further wrinkle: the copper(II) complex can dissociate under acidic HPLC conditions, so the GHK-Cu peak may be reported as the free tripeptide unless the method is designed to preserve the complex. A well-documented certificate states how this was handled instead of leaving the reader to guess.
Reading a blend certificate
For a blend, the useful certificate shows more than one number. The table below sets out what a reader should expect to be able to find, and what its absence implies.
| Item | What it should show | If it is missing |
|---|---|---|
| Lot number | Matches the vial in hand | No link between document and product |
| HPLC chromatogram | Peaks for each component, with method | Purity cannot be judged per component |
| Mass data | An observed mass for each component | Identity of individual components unproven |
| Composition statement | Intended mass ratio and how it was verified | Blend ratio is an assumption |
| Test date and laboratory | Stated clearly | Results cannot be placed in time or traced |
The V8 Peptides product page notes that the sequence or identity entry for the blend is reported on the certificate of analysis where published, and that batch documents are posted on the certificate of analysis page. Check that page for the lot you receive.
Questions worth asking any supplier
- Is each of the four components identity-confirmed separately, or is the vial tested only as an undifferentiated mixture?
- How is blend ratio accuracy verified: gravimetric control, mass spectrometry, or neither? See third-party testing explained.
- Is the CoA generated per production batch, with a lot number matching the vial received?
- Is endotoxin testing performed on the finished blend, given KPV's relevance to inflammatory signaling research?
- Is sale explicitly restricted to research use, with no usage instructions implying otherwise?
A supplier that answers these without hedging, and produces batch-specific, component-level documentation on request, is operating the way a laboratory reagent supplier should. Vague answers about how the blend is verified are reasons to source elsewhere. Criteria that apply to any order are in choosing a peptide supplier, and how blends differ from single vials is explained in peptide blends and research stacks.
Price relative to documentation
A four-component blend costs more to verify correctly than any single peptide in it, because each component needs its own analytical pass before the blend-level checks even start. Pricing that undercuts single-peptide-equivalent costs while still claiming full component and blend verification is worth scrutinizing. At minimum, ask to see the batch-specific CoA before assuming the claim is accurate. Another sanity check is to compare against the sibling blends: the GLOW vs. KLOW vs. Wolverine comparison shows which components overlap, which helps judge whether a quoted price reflects four components or fewer.
Handling and concentration math
The blend is supplied as a lyophilized powder and the product page specifies refrigeration at 2–8 °C, freezing for long-term storage, and protection from heat, moisture and light. Reconstituted concentration is total blend mass divided by diluent volume: 80 mg in 4 mL gives 20 mg/mL of total blend. Per-component concentration then depends on the documented ratio, which is one more reason the composition statement matters. The calculator handles the arithmetic once the ratio is known.
Where to buy a documented KLOW Stack
V8 Peptides lists the KLOW Stack as an 80 mg lyophilized blend of GHK-Cu, KPV, BPC-157 and TB-500 with a purity specification of ≥98% by HPLC and batch documentation published on the certificate of analysis page. The vial is on the KLOW Stack research vial product page. If a lab prefers to control each component separately, KPV and TB-500 are also listed as individual vials, and the GLOW stack is a related three-component blend.
Where to Buy the KLOW Stack FAQ
What is in the KLOW Stack?
Four research peptides in one lyophilized blend: GHK-Cu, KPV, BPC-157 and TB-500. The V8 Peptides listing is an 80 mg blend vial.
Why is a blend harder to verify than a single peptide?
Four synthesis processes must each be correct, and the components must be combined at the intended ratio. A missing or under-represented component can go unnoticed without per-component identity data.
Can one HPLC run confirm all four components?
It can show separate peaks, but it cannot by itself identify them. Mass spectrometry of each component confirms identity.
Why is GHK-Cu awkward to analyze?
It is a small copper(II) complex, and the metal can dissociate under acidic HPLC conditions, so the method determines what the peak represents.
Why does endotoxin matter for this blend?
KPV is studied in inflammatory-signaling work, and endotoxin contamination can provoke responses in cell culture that mimic or mask real effects.
How is the reconstituted concentration calculated?
Divide total blend mass by diluent volume: 80 mg in 4 mL is 20 mg/mL total blend. Per-component values depend on the documented ratio.
Where is the CoA published?
Batch documents are posted on the certificate of analysis page; the product page notes that identity details are reported on the certificate where published.
Are the components sold separately?
KPV and TB-500 are listed as individual vials, and BPC-157 and GHK-Cu are available separately as well.
For laboratory research use only; not for human consumption. This article is research education, not usage guidance.
References
- KLOW Stack research overview
- KLOW Stack purity testing
- KLOW Stack reconstitution and storage
- How to read a CoA
- Certificate of analysis page
- KLOW Stack product page
Research Use Only. Supplied strictly for laboratory research and development; not for human or veterinary use, consumption, or any clinical or diagnostic purpose.
